Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE

  • Read more about MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE
Australia
2022340743
Filed on 2024-02-23

MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE

  • Read more about MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE
Canada
3229861
Filed on 2024-02-21

MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE

  • Read more about MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE
Japan
2024-513749
Filed on 2024-02-29

COMPOSITIONS AND METHODS FOR TREATING CANCER

  • Read more about COMPOSITIONS AND METHODS FOR TREATING CANCER
US Application 18/266,455
Filed on 2023-06-09

GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES

  • Read more about GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES
China
202410413639.6
Filed on 2024-04-08

Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy

  • Read more about Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy
China
202410048366.X
Filed on 2024-01-12

METHODS FOR ISOLATING T CELL RECEPTORS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS

  • Read more about METHODS FOR ISOLATING T CELL RECEPTORS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS
Japan
2024-018658
Filed on 2024-02-09

Anti-Human Papillomavirus 16 E6 T Cell Receptors

  • Read more about Anti-Human Papillomavirus 16 E6 T Cell Receptors
Ireland
19180239.6
Filed on 2019-06-14

Anti-Human Papillomavirus 16 E6 T Cell Receptors

  • Read more about Anti-Human Papillomavirus 16 E6 T Cell Receptors
United Kingdom
19180239.6
Filed on 2019-06-14

Anti-Human Papillomavirus 16 E6 T Cell Receptors

  • Read more about Anti-Human Papillomavirus 16 E6 T Cell Receptors
Germany
19180239.6
Filed on 2019-06-14

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 237
  • Page 238
  • Page 239
  • Page 240
  • Page 241
  • Page 242
  • Page 243
  • Page 244
  • Page 245
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health